Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Stoke Therapeutics (STOK) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -357.38%.

  • Stoke Therapeutics' EBITDA Margin rose 17897.00% to -357.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.86%, marking a year-over-year increase of 64785.00%. This contributed to the annual value of -243.76% for FY2024, which is 93560.00% up from last year.
  • Stoke Therapeutics' EBITDA Margin amounted to -357.38% in Q3 2025, which was down 112.08% from -168.51% recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' EBITDA Margin registered a high of 71.22% during Q1 2025, and its lowest value of -1,226.72% during Q2 2023.
  • Its 3-year average for EBITDA Margin is -503.79%, with a median of -532.19% in 2024.
  • In the last 5 years, Stoke Therapeutics' EBITDA Margin tumbled by 44,542bps in 2023 and then spiked by 90,996bps in 2024.
  • Stoke Therapeutics' EBITDA Margin (Quarterly) stood at -768.88% in 2022, then crashed by 18,883bps to -957.71% in 2023, then soared by 90,996bps to -47.75% in 2024, then skyrocketed by 17,897bps to -357.38% in 2025.
  • Its last three reported values are -357.38% in Q3 2025, -168.51% for Q2 2025, and 71.22% during Q1 2025.